Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based international medical cannabis pharmaceutical company trading on AQSE Growth Market, announces the resignation of Nicholas (Nick) Ingrassia as a Non -Executive Director with immediate effect to focus on his other business commitments. Nick has sat on the Board of Apollon since it went public on the Aquis Growth market in April 2021. Nick Ingrassia, of Apollon Formularies, commented "It has been an honour and a pleasure to serve on the Apollon board alongside a group of such brilliant and dedicated directors. I believe Apollon has built an exciting intellectual property portfolio and brand. With a renewed outlook following its geographic shift, I believe the business is well positioned for success despite the challenging market environment in the medical cannabis space." Stene Jacobs, COO of Apollon Formularies, commented,"We extend our heartfelt appreciation to Nick for his service and dedication during his tenure as a valued member of our board. While we understand and respect his decision to step down, his impact will continue to resonate in our ongoing business. We extend our best wishes for his future endeavours." The Directors of the Company accept responsibility for the contents of this announcement. - End - Apollon Formularies Stene Jacobs stene@apollon.org.uk Peterhouse Capital Limited (Corporate Adviser) Tel: +44 207 220 9795 Guy Miller gm@peterhousecapital.com Blytheweigh (Financial PR/IR-London ) Tel: +44 207 138 3204 Tim Blythe tim.blythe@blytheweigh.com Megan Ray megan.ray@blytheweigh.com About Apollon Formularies plc Apollon Formularies is an international bio-medical pharmaceutical company specialising in cutting edge research and treatment of patients with cancer and chronic pain. Apollon is federally legal, licensed inJamaica , holds a suite of licences which allow the company to work with full spectrum oils inclusive of high levels of THC. Apollon's formulations are available by prescription to any licensed Jamaican doctor for their patients and for export to any country allowing legal import. Apollon is a publicly traded company listed on the Aquis Growth Market inLondon (AQSE: APOL) This information was brought to you by Cision http://news.cision.com https://news.cision.com/apollon-formularies-plc/r/resignation-of-non-executive-director,c3813149
APOL.AQSE
Apollon Formularies plc
Apollon Formularies Plc - Resignation of Non-Executive Director
3rd August 2023, 09:50
To continue viewing RNS, please confirm that you are a Private Investor*
* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
- Obtains access to the information in a personal capacity;
- Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
- Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
- Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
- Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
- Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.